<DOC>
	<DOCNO>NCT02303886</DOCNO>
	<brief_summary>Aim Investigation Methylene blue ( MB ) diaminophenothiazine antioxidant , anti-inflammatory property inhibitory effect nitric oxide . The aim study determine clinical effectiveness MB treatment neuropathic pain . Methods Ten patient neuropathic pain randomized receive one two treatment : methylene blue ( MB1 ) 2 mg/kg ( 10 mg/mL Methyltioninklorid , Apoteket , Umeå , Sweden ) methylene blue ( MB2 ) 0.02 mg/kg . Both MB solution infuse intravenously 60 minute . The sensory function pain evaluate baseline 60 min start infusion . A pain journal keep patient follow 5 day . Plasma urinary concentration 8-isoprostane-prostaglandin F2α ( 8-iso-PGF2α ) indicator oxidative injury , measure radioimmunoassay ( RIA ) . A panel 92 proteins biomarkers determine Proximity Extension Assay ( PEA ) prior infusion . comparison control group . MB infusion produce enhancement prolactin .</brief_summary>
	<brief_title>Methylene Blue Intravenously Chronic Neuropathic Pain</brief_title>
	<detailed_description>Patients Study participant screen pool patient chronic treatment resistant neuropathic pain eligible participate study give write informed consent Study design The patient visit Pain Clinic twice . Oral write information study provide informed consent obtain . Demographic data ( date birth , sex , ethnic background , medical surgical history ) record . Information patient ` assessment record injection , include current medication ( successful non-successful ) treatment attempt . The investigator ( AM ) perform study procedure assessment . Assessments sensory function perform drug administration . Administration study drug Ten patient randomize computer generate random list receive either methylene blue 2mg/kg ( 10 mg/mL Methyltioninklorid , Apoteket , Umeå , Sweden ) methylene blue 0.02 mg/kg ( serve control ) , infuse intravenously 60 minute . After monitor electrocardiography , noninvasive arterial blood pressure , pulse oximetry attach , dedicate 20-gauge cannula insert dorsum nondominant hand administration study drug . The pain measure baseline 60 min start infusion ( NRS scale ) also pain diary next 24 hour follow 5 day . ECG , pulse , blood pressure , O2 saturation , continuously record infusion . Blood urine sample take infusion MB . Neither subject experiment person examine patient know concentration MB infusion . The infusion methylene blue sterile saline ( NaCl 0.9 % ) prepare another person access randomization list involve monitoring patient . The infusion bag cover opaque red wrappes infusion set opaque . Pain Assessment perform Before MB administration , Evaluation sensory function perform use bedside examination accord EFNS guideline : light touch , pinprick sense , warmth ( 40° ) cold ( 25° ) temperature stimulus test . The contralateral uninjured side serve within-patient control . The patient compare sensation side report hypoesthesia , hyperesthesia , allodynia simply normal sensation different stimulus . The pain recording determine infusion MB . Patients keep diary could pick pain level scale 0 10 ( NRS ) every 6 hour infusion first 24 hour 8 hour next 5 day . Peripheral venous blood drawn fast subject use 19-gauge needle . Urine collect additive-free tube . Plasma prepare blood collect tube contain heparin centrifugation ( 3500x g 12 min ) . Urine plasma sample store −70◦C analysis . Blood urine sample collect infusion MB . Plasma urine concentration isoprostane 8-iso-PGF2 alpha ( indicator oxidative injury ) , Proximity Extension Assay ( PEA ) find specificity detection analysis increase range target molecule . PEA technology involve study panel 92 oligonucleotide label antibody probe pair ( Proseek assay kit ) , Non-parametric statistical method perform author GraphPad PRISM 5.0 ( GraphPad Software , La Jolla , San Diego , CA , www.graphpad.com 5.0 ) . Data present mean SD 95 % confidence interval . The level significance set p value &lt; .05 .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>Female male subject &gt; 18 year age Be able understand comply requirement study Patients history persistent peripheral central neuropathic pain interfere daily activity least 3 month duration Patients previous unsuccessful treatment neuropathic pain Spontaneous evoke pain upon standardized test ( mechanical , movement ) &gt; 50 100 mm VAS scale Informed write consent Any condition may confound assessment pain ( acute pain ) Any condition/disease could interfere study measurement , e.g . peripheral vascular disease , diabetes mellitus , alcohol/opioids addiction Noncooperation , insufficient Swedish language Treatment antidepressant , antiepileptic , opioids , lidocaine patch accept day day visit Pregnancy Treatment NO release drug , anticytokine therapy Diabetes mellitus type I , malignancy , increase pulmonary hypertension , cardiac ischemic disease , decrease glomerular filtration rate &lt; 30 ml/min , decrease liver function , Glu6PDH deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>